"rationale","id","name","label","description","uuid:ID","instanceType"
"The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyDesign_1","Study Design 1","","The main design for the study","610bd2bf-d9b7-413a-a033-9d8bf5f5838e","StudyDesign"
